ScoreWhy is Venus Remedies Ltd ?
1
The company is Net-Debt Free
2
Healthy long term growth as Operating profit has grown by an annual rate 56.81%
3
With a growth in Net Profit of 139.27%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 7 consecutive quarters
- PAT(Latest six months) At Rs 70.47 cr has Grown at 130.29%
- PBT LESS OI(Q) At Rs 27.42 cr has Grown at 198.37%
- NET SALES(Latest six months) At Rs 438.26 cr has Grown at 31.95%
4
With ROE of 15.5, it has a Fair valuation with a 3.2 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 210.19%, its profits have risen by 153.1% ; the PEG ratio of the company is 0.1
5
Consistent Returns over the last 3 years
- Along with generating 210.19% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Venus Remedies should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Venus Remedies for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Venus Remedies
210.19%
3.90
53.95%
Sensex
-2.63%
-0.19
13.57%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.65%
EBIT Growth (5y)
56.81%
EBIT to Interest (avg)
54.78
Debt to EBITDA (avg)
0.54
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
1.14
Tax Ratio
23.37%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.81%
ROCE (avg)
9.53%
ROE (avg)
8.61%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
18
Industry P/E
37
Price to Book Value
3.15
EV to EBIT
14.31
EV to EBITDA
12.05
EV to Capital Employed
3.49
EV to Sales
2.47
PEG Ratio
0.12
Dividend Yield
0.64%
ROCE (Latest)
21.23%
ROE (Latest)
15.49%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
PAT(Latest six months)
At Rs 70.47 cr has Grown at 130.29%
PBT LESS OI(Q)
At Rs 27.42 cr has Grown at 198.37%
NET SALES(Latest six months)
At Rs 438.26 cr has Grown at 31.95%
ROCE(HY)
Highest at 19.85%
-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 29.61 cr
Loading Valuation Snapshot...
Here's what is working for Venus Remedies
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 27.42 cr has Grown at 198.37%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 22.97 cr has Grown at 139.3%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
At Rs 178.86 cr has Grown at 30.38%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Venus Remedies
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 29.61 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
